| Literature DB >> 27965804 |
Barbara Seebacher1, Raija Kuisma1, Angela Glynn1, Thomas Berger2.
Abstract
BACKGROUND: Novel physiotherapy approaches such as motor imagery and rhythmic auditory stimulation have been shown to improve walking in people with multiple sclerosis (MS). Rhythmic cued motor imagery was used in this study, whose objectives were to evaluate the feasibility of a larger randomised controlled trial (RCT) in people with MS and to obtain information on walking.Entities:
Keywords: Multiple sclerosis; Physiotherapy; Rhythmic cued motor imagery; Walking
Year: 2015 PMID: 27965804 PMCID: PMC5154106 DOI: 10.1186/s40814-015-0021-3
Source DB: PubMed Journal: Pilot Feasibility Stud ISSN: 2055-5784
Fig. 1CONSORT flow diagram
Participants’ baseline characteristics
| Parameter | Group A | Group B | Group C |
|---|---|---|---|
| Music cued motor imagery | Metronome cued motor imagery | Control group | |
| Females to males | 10:0 | 7:3 | 5:5 |
| Age (years)a | 47.3 (38.4, 56.2) | 41.8 (34.8, 48.8) | 46.1 (39.8, 52.5) |
| EDSSb | 3 (1.5, 4.5) | 2.5 (1.5, 4.5) | 2.5 (1.5, 4.0) |
| MFIS total scoreb | 35 (3, 67) | 32 (17, 50) | 33.5 (0, 48) |
| Participants with fatigue (MFIS total score ≥38) | 4/10 | 2/10 | 4/10 |
| T25FW (s)a | 6.1 (4.5, 7.6) | 5.4 (4.5, 6.2) | 5.2 (4.3, 6.1) |
| 6MWT (m)a | 453.1 (365.0, 541.1) | 428.2 (352.8, 503.6) | 484.7 (399.5, 569.8) |
EDSS Expanded Disability Status Scale, MFIS Modified Fatigue Impact Scale, T25FW Timed 25-Foot Walk, s seconds, 6MWT 6-Minute Walk Test, m metres
aMean (95 % confidence interval)
bMedian (range)
Follow-up data for each study group
| Parameter | Group A | Group B | Group C |
|---|---|---|---|
| Music cued motor imagery | Metronome cued motor imagery | Control group | |
| MFIS total score (points) | |||
| At follow-upa | 28 (0, 53) | 20 (3, 50) | 29 (0, 46) |
| Participants with fatigue (MFIS total score ≥38) | 2/10 | 2/10 | 2/10 |
| Change to baselinea | −9.5 (−31, 5) | −13 (−28, 7) | −3 (−17, 4) |
| T25FW (seconds) | |||
| At follow-upb | 5.2 (3.6, 6.7) | 4.5 (3.7, 5.2) | 5.5 (4.5, 6.6) |
| Change to baselineb | −0.9 (−1.3, −0.5) | −0.9 (−1.3, −0.5) | 0.4 (−0.3, 1.1) |
| Effect sizec | 1.27 (0.26, 2.17) | 1.27 (0.26, 2.17) | |
| Participants with clinically significant improvement (≥20 %)d | 3/10 | 3/10 | 0/10 |
| 30 % (7, 65 %) | 30 % (7, 65 %) | 0 % (0) | |
| 6MWT (metres) | |||
| At follow-upb | 521.1 (428.8, 613.5) | 521.1 (454.1, 588.0) | 475.3 (384.9, 565.8) |
| Change to baselineb | 68.1 (51.4, 84.7) | 92.9 (55.2, 130.5) | −9.4 (−35.6, 16.9) |
| Effect sizec | 1.91 (0.79, 2.88) | 1.72 (0.64, 2.67) | |
| Participants with clinically significant improvement (≥20 %)d | 2/10 | 6/10 | 0/10 |
| 20 % (2, 56 %) | 60 % (26, 88 %) | 0 % (0) | |
With walking speed (T25FW), improvement is indicated by a minus and worsening by a plus; with walking distance (6MWT), improvement is indicated by a plus and worsening by a minus
T25FW Timed 25-Foot Walk, 6MWT 6-Minute Walk Test
aMedian (range)
bMean (95 % confidence interval)
cCohen’s d, with 95 % confidence interval, based on corrected estimates of pooled standard deviation for 80 % of trials [52]
dPercentage (95 % confidence interval)